LT5045B - Prolonguoto išsiskyrimo granulės, turinčios stavudino - Google Patents

Prolonguoto išsiskyrimo granulės, turinčios stavudino Download PDF

Info

Publication number
LT5045B
LT5045B LT2002099A LT2002099A LT5045B LT 5045 B LT5045 B LT 5045B LT 2002099 A LT2002099 A LT 2002099A LT 2002099 A LT2002099 A LT 2002099A LT 5045 B LT5045 B LT 5045B
Authority
LT
Lithuania
Prior art keywords
stavudine
granules
granules according
dosage form
drug
Prior art date
Application number
LT2002099A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2002099A (en
Inventor
Rober Abramowitz
Denise M. O'donoghue
Nemichand B. Jain
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT2002099A publication Critical patent/LT2002099A/xx
Publication of LT5045B publication Critical patent/LT5045B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LT2002099A 2000-03-30 2002-09-06 Prolonguoto išsiskyrimo granulės, turinčios stavudino LT5045B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19358800P 2000-03-30 2000-03-30

Publications (2)

Publication Number Publication Date
LT2002099A LT2002099A (en) 2003-04-25
LT5045B true LT5045B (lt) 2003-08-25

Family

ID=22714247

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002099A LT5045B (lt) 2000-03-30 2002-09-06 Prolonguoto išsiskyrimo granulės, turinčios stavudino

Country Status (26)

Country Link
US (1) US7135465B2 (de)
EP (1) EP1267879A2 (de)
JP (1) JP2003528905A (de)
KR (1) KR20030011805A (de)
CN (1) CN1187052C (de)
AR (1) AR027748A1 (de)
AU (1) AU2001249591A1 (de)
BG (1) BG107157A (de)
BR (1) BR0109602A (de)
CA (1) CA2404687A1 (de)
CZ (1) CZ20023003A3 (de)
EE (1) EE200200564A (de)
GE (1) GEP20043285B (de)
HU (1) HUP0302631A2 (de)
IL (1) IL151475A0 (de)
LT (1) LT5045B (de)
LV (1) LV12939B (de)
MX (1) MXPA02009534A (de)
NO (1) NO20024645L (de)
NZ (1) NZ522250A (de)
PE (1) PE20011179A1 (de)
PL (1) PL366089A1 (de)
RU (1) RU2239435C2 (de)
SK (1) SK12822002A3 (de)
WO (1) WO2001074329A2 (de)
ZA (1) ZA200207760B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
BR0312206A (pt) * 2002-06-27 2005-04-12 Cilag Ag Formulações de pélete esférico
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100548309C (zh) * 2004-11-24 2009-10-14 东北制药总厂 司他夫定缓释片剂
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
WO2007026156A1 (en) * 2005-08-31 2007-03-08 Cipla Limited Pharmaceutical combinations containing lamivudine, stavudine and nevirapine
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US20190083399A9 (en) * 2006-04-03 2019-03-21 Isa Odidi Drug delivery composition
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
CN102319181B (zh) * 2011-09-08 2014-07-16 广东大华农动物保健品股份有限公司 一种微囊型动物药品的包被工艺
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
JP2017522321A (ja) * 2014-07-17 2017-08-10 ダウ グローバル テクノロジーズ エルエルシー エチルセルロース分散系とフィルム
CN105511174A (zh) * 2016-01-05 2016-04-20 深圳市华星光电技术有限公司 液晶显示面板和显示装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978655A (en) 1986-12-17 1990-12-18 Yale University Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671963A (en) 1983-10-28 1987-06-09 Germino Felix J Stearate treated food products
US4670270A (en) 1984-05-07 1987-06-02 Germino Felix J Stearate treated food products
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
WO1993012768A1 (en) 1991-12-30 1993-07-08 Fmc Corporation Microcrystalline cellulose spheronization composition
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
GB9403449D0 (en) 1994-02-23 1994-04-13 Wellcome Found Therapeutic benzonitriles
DE69512220T2 (de) 1994-03-07 2000-03-16 Vertex Pharmaceuticals Inc. Sulfonamidderivate als aspartylprotease-inhibitoren
EP0814806A1 (de) 1995-02-23 1998-01-07 Janssen Pharmaceutica N.V. Verwendung von verschweissten benzothiazole als neuroprotectants
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1997022248A1 (en) 1995-12-15 1997-06-26 Cryopreservation Technologies Cc Composition for organ cryopreservation and treatment of viral and bacterial infections
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US5883252A (en) 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5766623A (en) 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US5780055A (en) 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US5905068A (en) 1996-09-24 1999-05-18 Abbott Laboratories Retroviral protease inhibiting compounds
ATE314054T1 (de) 1996-10-25 2006-01-15 Shire Lab Inc Osmotisches verabreichungssystem für lösliche dosen
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6136827A (en) 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
PT1003476E (pt) 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
JP2002522354A (ja) * 1997-09-19 2002-07-23 シャイア ラボラトリーズ，インコーポレイテッド 固溶体ビードレット
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6013644A (en) 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
BR9813691A (pt) 1997-12-19 2000-10-10 Takeda Chemical Industries Ltd Composição farmacêutica para antagonizar o ccr5, uso do composto ou um sal deste em combinação com um inibidor de protease e/ou um inibidor da transcriptase reversa, e, processo para antagonizar o ccr5.
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
CA2335617C (en) 1998-06-24 2009-12-15 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
US6194430B1 (en) 1999-03-31 2001-02-27 The Procter & Gamble Company Viral treatment
US6136835A (en) 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978655A (en) 1986-12-17 1990-12-18 Yale University Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERTIL ABRAHAMSSON ET AL.: "Gastro-intestinal transit of a multiple-unit formulation (metoprolol CR/ZOK) and a non-disintegrating tablet with the emphasis on colon", INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, pages 229 - 235

Also Published As

Publication number Publication date
NO20024645D0 (no) 2002-09-27
EP1267879A2 (de) 2003-01-02
EE200200564A (et) 2004-06-15
WO2001074329A2 (en) 2001-10-11
NO20024645L (no) 2002-09-27
SK12822002A3 (sk) 2003-02-04
CN1187052C (zh) 2005-02-02
PE20011179A1 (es) 2001-12-06
MXPA02009534A (es) 2003-05-14
ZA200207760B (en) 2004-01-30
LT2002099A (en) 2003-04-25
LV12939B (en) 2003-04-20
RU2239435C2 (ru) 2004-11-10
AR027748A1 (es) 2003-04-09
HUP0302631A2 (hu) 2003-11-28
AU2001249591A1 (en) 2001-10-15
KR20030011805A (ko) 2003-02-11
RU2002126540A (ru) 2004-03-27
PL366089A1 (en) 2005-01-24
BR0109602A (pt) 2004-06-29
GEP20043285B (en) 2004-07-26
NZ522250A (en) 2004-09-24
CN1420774A (zh) 2003-05-28
WO2001074329A3 (en) 2002-05-10
CA2404687A1 (en) 2001-10-11
CZ20023003A3 (cs) 2002-11-13
US7135465B2 (en) 2006-11-14
US20020002147A1 (en) 2002-01-03
IL151475A0 (en) 2003-04-10
JP2003528905A (ja) 2003-09-30
BG107157A (en) 2003-06-30

Similar Documents

Publication Publication Date Title
EP1123087B1 (de) Orales system zur verabreichung von gepulsten dosen eines arzneistoffs
LT5045B (lt) Prolonguoto išsiskyrimo granulės, turinčios stavudino
US8968777B2 (en) Tranexamic acid formulations with reduced adverse effects
US5158777A (en) Captopril formulation providing increased duration of activity
EP1562573B1 (de) Pharmazeutische pellets enthaltend tamsulosin sowie deren herstellungsverfahren
DK2204168T3 (en) Tetracycline for administration once a day
HU196708B (en) Process for producing pharmaceutical composition comprising omeprazol and suitable for treating deseases of the digestive system
NZ205894A (en) Pharmaceutical compositions containing mopidamol(2,6-bis(diethanolamino)-4-piperidino-pyrimido(5,4-d)pyrimidine)
US8460702B2 (en) Pharmaceutical compositions
AU1456999A (en) Novel oral dosage form for carvedilol
AU2004251439A1 (en) Tablet comprising fluvastatin and carmellose calcium
CZ146494A3 (en) Ipsapirone healing preparation
AU2004200325B2 (en) Oral Pulsed Dose Drug Delivery System
AU2006236052B2 (en) Oral pulsed dose drug delivery system

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20060329